By: Eric Rosenbaum
WeightWatchers' embrace of weight loss and obesity drugs like Novo Nordisk's Ozempic and Wegovy is a big deal, but the market still isn't sold on its future.
Eric Rosenbaum is an editor for CNBC and has been with the company since 2010. His work covers a range of topics including technology, business, and economics. He has also been featured in various publications such as The West Australian and NBC DFW.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Eric Rosenbaum's coverage primarily focuses on business, finance, economy, and technology. His articles often cite data and provide investment analysis. To effectively reach out to him, consider providing data-driven insights or expert opinions related to artificial intelligence (AI), the Biden administration’s economic policies, small business trends, and technological advancements with a focus on their impact on the economy and businesses. This could include offering unique perspectives or new research findings in these areas that align with his coverage interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .